Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 13/20 | 0.42 |
| ▸ | FPR3 | P25089 | 9/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 2/20 | 0.38 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210138 | 0.90 | CCR1 (0.39) | NAMPT | |
| SCHEMBL207173 | 0.90 | NAMPT (0.38) | NAMPT | |
| SCHEMBL208311 | 0.86 | BCL2 (0.40) | BCL2 | |
| SCHEMBL208667 | 0.85 | FPR2 (0.45) | FPR2FPR3CHRNA7NAMPT | |
| SCHEMBL209570 | 0.83 | — | — | |
| SCHEMBL209919 | 0.81 | KMT2A (0.34) | NAMPT | |
| SCHEMBL210826 | 0.80 | KMT2A (0.35) | NAMPT | |
| SCHEMBL209539 | 0.79 | NTRK1 (0.36) | — | |
| SCHEMBL207795 | 0.79 | NPC1 (0.39) | — | |
| SCHEMBL208375 | 0.75 | CTSL (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | FPR2 51/4885FPR3 40/4885CHRNA7 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.